Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasia

International Urology and Nephrology

Volumn 33, Issue 3, 2001, Pages 407-412

  Pool, James L ^a   Kirby, Roger S ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; DOXAZOSIN; INDORAMIN; PHENOXYBENZAMINE; PLACEBO; PRAZOSIN; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SELECTIVITY; HUMAN; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT COMPLIANCE; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RECEPTOR DENSITY; RETROGRADE EJACULATION; REVIEW; AGED; CLASSIFICATION; MALE; METABOLISM; MIDDLE AGED;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BLOOD-BRAIN BARRIER; DOXAZOSIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 0035545309     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019504703485     Document Type: Review

References (44)

1. Benign prostatic hyperplasia. Its natural history, epidemiologic characteristics, and surgical treatment
2. Benign prostatic hyperplasia
3. International Union of Pharmacology nomenclature of adrenoceptors
4. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update
5. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
6. The development of benign prostatic hyperplasia
7. New words for old: Lower urinary tract symptoms for "prostatism"
8. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy
9. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy
10. Some clinical implications of adrenergic receptors in the urinary tract
11. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle
12. Rationale for alpha-blockade in BPH therapy
13. Prostatic and extraprostatic alpha-adrenoceptors - Contributions to the lower urinary tract symptoms in benign prostatic hyperplasia
14. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: Past, present and future
15. Prostatic alpha 1-adrenoceptors and uroselectivity
16. Uroselectivity
17. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype
18. The concept of uroselectivity
19. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension
20. Alpha-blockers clinical results
21. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction
22. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases
23. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study
24. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate
25. A three-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction
26. Morning vs. evening dosing with doxazosin in benign prostatic hyperplasia: Efficacy and safety
27. Terazosin and doxazosin in normotensive men with symptomatic prostatism: A pilot study to determine the effect of dosing regimen on efficacy and safety
28. 29-Week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study
29. Doxazosin treatment in patients with prostatic obstruction
30. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension
31. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study
32. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies
33. Doxazosin: An update of its clinical pharmacology and therapeutic applications in the treatment of hypertension and BPH
34. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
35. Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients
36. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group
37. Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men
38. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study
39. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia
40. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled on other antihypertensive medications: A randomised, placebo-controlled study
41. Long-term effects on plasma lipids of diet and drugs to treat hypertension
42. Indoramin in the treatment of prostatic bladder outflow obstruction
43. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group
44. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group